<DOC>
	<DOCNO>NCT00268398</DOCNO>
	<brief_summary>PURPOSE : This randomized phase III trial study two different combination chemotherapy regimens compare well work treat patient colorectal cancer resectable metastasis .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Colorectal Cancer Resectable Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare 2-year disease-free survival rate patient treat regimen . Secondary - Compare overall survival patient treat regimen . - Compare tolerability regimens patient . - Compare quality life patient treat regimen . - Compare objective response rate , postoperative complication rate , transfuse rate patient metastasis surgery , - Determine pharmacogenetics regimens patient . OUTLINE : This randomize , open-label , multicenter phase III study . Patients stratify accord prior chemotherapy ( perioperative v postoperative ) , prior treatment ( surgery v radiotherapy without surgery ) , Blumgart score ( 0-1 v 2-3 vs 4-5 ) . Patients randomize 1 2 treatment arm . - Arm I ( FOLFOX 4 ) : Patients receive FOLFOX 4 combination chemotherapy comprise oxaliplatin 85mg/m² IV 2 hour , leucovorin calcium IV 2 hour , fluorouracil IV bolus /15min fluorouracil continuously 22 hour day 1 . Treatment repeat every 2 week 12 course absence disease progression unacceptable toxicity . - Arm II ( FOLFOX 7 FOLFIRI ) : Patients receive FOLFOX 7 combination chemotherapy comprise high-dose oxaliplatin 130mg/m² IV 2 hour leucovorin calcium IV 2 hour day 1 fluorouracil IV 46 hour day 1 2 . Treatment repeat every 2 week 6 course absence disease progression unacceptable toxicity . Patients receive FOLFIRI combination chemotherapy comprise irinotecan hydrochloride 180mg/m² IV 30-90 minute leucovorin calcium fluorouracil IV bolus /15min day 1 , fluorouracil IV continuously 46 hour day 1 2 . Treatment repeat every 2 week 6 course absence disease progression unacceptable toxicity . Patients arm undergone prior resection metastatic lesion may undergo surgery 6 course chemotherapy chemotherapy complete . Quality life assess baseline course 4 , 8 , 12 . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 284 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>MAIN ELIGIBILITY CRITERIA DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Resectable resect metastatic disease , PATIENT CHARACTERISTICS : WHO performance status 02 Alkaline phosphatase ≤ 5 time upper limit normal ( ULN ) Bilirubin ≤ 2 time normal Creatinine ≤ 135 mmol/L creatinine clearance ≥ 60 mL/min SGOT SGPT ≤ 3 time ULN No peripheral neuropathy affect normal function No unresolved complication prior surgery PRIOR CONCURRENT THERAPY : At least 1 year since prior FOLFOX 4 FOLFIRI regimen adjuvant set No concurrent participation another clinical trial Recovered prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>resectable metastasis</keyword>
</DOC>